ALL libraries (COBIB.SI union bibliographic/catalogue database)
PDF
  • Assessment of letrozole and tamoxifen alone and in sequence for postmenopausalwomen with steroid hormone receptor-positive breast cancer : the BIG 1-98 randomised clinical trial at 8.1 years median follow-up
    Regan, Meredith M. ...
    Background: Postmenopausal women with hormone receptor-positive early breast cancer have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials assessing endocrine ... therapies for this patient population need extended follow-up. We present an update of efficacy outcomes in the Breast International Group (BIG) 1-98 study at 8 1 years median follow-up. Methods: BIG 1-98 is a randomised, phase 3, double-blind trial of postmenopausal women with hormone receptor-positive early breast cancer that compares 5 years of tamoxifen or letrozole monotherapy, or sequential treatment with 2 years of one of these drugs followed by 3 years of the other.Randomisation was done with permuted blocks, and stratified according tothe two-arm or four-arm randomisation option, participating institution, andchemotherapy use. Patients, investigators, data managers, and medical reviewers were masked. The primary efficacy endpoint was disease-free survival(events were invasive breast cancer relapse, second primaries šcontralateral breast and non-breastđ, or death without previous cancer event). Secondary endpoints were overall survival, distant recurrence-free interval (DRFI), and breast cancer-free interval (BCFI). The monotherapy comparison included patients randomly assigned to tamoxifen or letrozole for 5years. In 2005, after a significant disease-free survival benefit was reported for letrozole as compared with tamoxifen, a protocol amendment facilitated the crossover to letrozole of patients who were still receiving tamoxifen alone; Cox models and Kaplan-Meier estimates with inverse probability of censoring weighting (IPCW) are used to account for selective crossover to letrozole of patients (n=619) in the tamoxifen arm. (Abstract truncated at 2000 characters)
    Source: The lancet oncology. - ISSN 1470-2045 (Vol. 12, iss. 12, 2011, str. 1101-1108)
    Type of material - article, component part
    Publish date - 2011
    Language - english
    COBISS.SI-ID - 29393113
    DOI

source: The lancet oncology. - ISSN 1470-2045 (Vol. 12, iss. 12, 2011, str. 1101-1108)
loading ...
loading ...
loading ...